Analisis Biaya dan Luaran Klinik Terapi Remdesivir dibandingkan Favipiravir pada COVID-19 Derajat Sedang: Perspektif Provider

https://doi.org/10.22146/jmpf.87168

Laduna Aniq(1), Tri Murti Andayani(2*), Dwi Endarti(3)

(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


The COVID-19 pandemic cases affect health and the economy and have become a burden for the global community. Effective and specific antiviral for COVID-19 is still controversial and has yet to be found. Antiviral use is the main mitigation strategy that tends to be more cost-effective but varies in effectiveness and cost depending on various factors. This study aims to evaluate the effectiveness, safety, and cost of antiviral therapy in moderate COVID-19. This observational-analytic study used a retrospective cohort design. Subjects were hospitalized patients with moderate COVID-19 who received antivirals in July-October 2021 and January-March 2022. Therapy effectiveness was measured by lowered NLR (Neutrophil-to-Lymphocyte Ratio) to a normal level and length of stay (LOS). Drug safety includes adverse drug events. The cost of therapy was calculated based on the hospital’s perspective (provider), using direct medical costs. A total of 170 patients were divided into two groups (94 patients remdesivir and 76 patients favipiravir). In this arm, there were 45 patients with lowered NLR (21 patients reached the target and 24 patients did not). The effectiveness of favipiravir and remdesivir was 70.6% and 32.1%. Remdesivir may lower NLR (2.92) versus favipiravir (1.55). Favipiravir had a shorter LOS than remdesivir (8 vs 9 days). Adverse drug events observed in remdesivir were nausea (47.9%) and abdominal pain (22.3%), while in favipiravir nausea (53.9%) and vomiting (22.4%). The average total cost of remdesivir is higher than favipiravir (IDR 19,772,985 vs IDR 13,819,727). Favipiravir has higher efficacy and a shorter LOS with a lower average total cost than remdesivir.


Keywords


antiviral; biaya; COVID-19; efektivitas; farmakoekonomi

Full Text:

PDF


References

  1. Burhan E, Susanto AD, Nasution SA, et al. Pedoman Tatalaksana COVID-19 Edisi 4, Jakarta. Published online 2022:176.
  2. Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas: National Public Health Journal. 2021;16(4). doi:10.21109/kesmas.v16i4.5433
  3. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. Adv Ther. 2021;38(4):1811-1831. doi:10.1007/s12325-021-01654-5
  4. Alkhatip AAAMM, Kamel MG, Hamza MK, et al. The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. Expert Review of Molecular Diagnostics. 2021;21(5):505-514. doi:10.1080/14737159.2021.1915773
  5. Selanno Y, Widaningsih Y, Esa T, Arif M. Analysis of Neutrophil Lymphocyte Ratio and Absolute Lymphocyte Count as Predictors of Severity of COVID-19 Patients. Indonesian J Clin Pathol Med Lab. 2021;27(2):184-189. doi:10.24293/ijcpml.v27i2.1738
  6. fırat asuman akkaya. Biochemical Markers and NLR Levels in Covid-19 Infection: In Cases With Severe Pulmonary Involvement According to CT Score. Int J Med Biochem. Published online 2022. doi:10.14744/ijmb.2022.14890
  7. Han Q, Wen X, Wang L, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34(5). doi:10.1002/jcla.23191
  8. Song CY, Xu J, He JQ, Lu YQ. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. Published online March 8, 2020:2020.03.05.20031906. doi:10.1101/2020.03.05.20031906
  9. Kerboua KE. NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19. Immunological Investigations. 2021;50(1):92-100. doi:10.1080/08820139.2020.1773850
  10. Mousavi-Nasab SD, Mardani R, Azadani HN, Sabeti S, Darazam IA, Ahmadi N. Neutrophil to lymphocyte ratio and C-reactive protein level as prognostic markers in mild versus severe COVID-19 patients. :6.
  11. Dawoud DM, Soliman KY. Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations. Value in Health. 2020;23(11):1409-1422. doi:10.1016/j.jval.2020.07.002
  12. Yavuz SŞ, Çeli̇Kyurt İK. An update of anti-viral treatment of COVID-19. Turk J Med Sci.:19.
  13. Arnold RJG, ed. Pharmacoeconomics: From Theory to Practice. Second edition. CRC Press; 2020.
  14. Andayani TM. Farmakoekonomi Prinsip Dan Metodologi. Bursa Ilmu; 2013.
  15. Rezapour A, Behroozi Z, Nasirzadeh M, et al. Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review. Infect Dis Poverty. 2023;12(1):39. doi:10.1186/s40249-023-01092-1
  16. Oksuz E, Malhan S, Gonen MS, et al. Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey. Adv Ther. 2021;38(9):4935-4948. doi:10.1007/s12325-021-01874-9
  17. Jo Y, Jamieson L, Edoka I, et al. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. Open Forum Infectious Diseases. 2021;8(3):ofab040. doi:10.1093/ofid/ofab040
  18. Rafia R, Martyn-St James M, Harnan S, Metry A, Hamilton J, Wailoo A. A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales. Value in Health. 2022;25(5):761-769. doi:10.1016/j.jval.2021.12.015
  19. Kelton K, Klein T, Murphy D, et al. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. Adv Ther. 2022;39(1):562-582. doi:10.1007/s12325-021-01982-6
  20. Fathurrahman MH, Simanjutak N, Sopiah NS. Analisis Efektivitas Biaya Penggunaan Obat Pada Pasien Rawat Inap Penyakit COVID-19 Kategori Suspek Non-Comorbid Dengan Terapi Obat Kombinasi Antivirus dan Antibiotik di Salah Satu Rumah Sakit Kota Bandung Periode Juli – Desember 2021. Pharma Xplore Jurnal Sains dan Ilmu Farmasi. 2023;Vol. 8 Nomor 1.
  21. Rahmandani A, Sarnianto P, Anggriani Y, Dermawan Purba F. Analisis Efektivitas Biaya Penggunaan Obat Antivirus Oseltamivir dan Favipiravir pada Pasien Covid-19 Derajat Sedang di Rumah Sakit Sentra Medika Cisalak Depok. Maj Farmasetika. 2021;6:133. doi:10.24198/mfarmasetika.v6i0.36667
  22. Yusransyah Y, Udin B, Mursyid A, Mardiyanto Y, Uli ES, Suryana N. Analisis Efektivitas Biaya pada Pasien Covid-19 yang Menggunakan Terapi Oksigen dengan dan Tanpa Diberikan Remdesivir di RSUD Kabupaten Tangerang. Jurnal Farmasi Indonesia. 2022;Vol.14 Nomor 1. doi:doi.org/10.35617/jfionline.v14i1.75
  23. Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Haematology Group, ed. Cochrane Database of Systematic Reviews. 2023;2023(1). doi:10.1002/14651858.CD014962.pub2
  24. Aung KZL, Yılmaz R, Güngördü E, Aşar S, Tekdos Şeker Y. Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia? tybd. 2021;19(1):102-109. doi:10.4274/tybd.galenos.2021.04706
  25. Munir MA, Kuganda H, Basry A. The Efficacy and Safety of Antivirus Drugs for COVID-19: A Systematic Review. Systematic Reviews in Pharmacy. 2020;11(7):5.
  26. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/413/2020 Tentang Pedoman Pencegahan Dan Pengendalian Coronavirus Disease 2019 (COVID-19).; 2020.
  27. Menteri Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 23 Tahun 2023 Tentang Pedoman Penanggulangan Corona Virus Disease 2019 (COVID-19). Published online 2023.
  28. Lemeshow S, World Health Organization, eds. Adequacy of Sample Size in Health Studies. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss; 1990.
  29. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10):1192-1198. doi:10.1016/j.eng.2020.03.007
  30. Dahlan MS. Analisis Multivariat Regresi Logistik. 2nd ed. PT Epidemiologi Indonesia; 2019.
  31. Sastroasmoro S, Sofyan I. Dasar-Dasar Metodologi Penelitian Klinis. 5th ed. Sagung Seto; 2014.
  32. Rauf A, Abu-Izneid T, Olatunde A, et al. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. IJERPH. 2020;17(21):8155. doi:10.3390/ijerph17218155
  33. Ariza D, Kesrianti AM, Ruslan TA. Neutrophil Lymphocyte Ratio (NLR) in COVID-19 Patients Receiving Convalescent Plasma Therapy. IJMLST. 2022;4(2):139-147. doi:10.33086/ijmlst.v4i2.2460
  34. Adane T, Melku M, Worku YB, et al. The Association between Neutrophil-to-Lymphocyte Ratio and Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res. 2023;2023:3117396. doi:10.1155/2023/3117396
  35. He F, Deng Y, Li W. Coronavirus disease 2019: What we know?, J Med Virol. 2020;92:719-725. DOI: 10.1002/jmv.25766.
  36. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine & Growth Factor Reviews. 2020;53:66-70. doi:10.1016/j.cytogfr.2020.05.002
  37. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab Syndr. 2020;14(5):1133-1142. doi:10.1016/j.dsx.2020.07.005
  38. Zhang J, Wu J, Sun X, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. Epidemiol Infect. 2020;148:e106. doi:10.1017/S095026882000117X
  39. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Published online April 13, 2020. doi:10.1001/jama.2020.6019
  40. WHO. Therapeutics and COVID-19: Living Guideline. World Health Organization; 2022. WHO reference number: WHO/2019-nCoV/therapeutics/2022.2
  41. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
  42. Joshi S, Vora A, Venugopal K, et al. Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India. POR. 2022;Volume 13:33-41. doi:10.2147/POR.S364066
  43. Adhikari P, Koirala J, Shrestha A, et al. Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial. International Journal of Infectious Diseases. 2022;116:S45-S46. doi:10.1016/j.ijid.2021.12.109
  44. Krongsut S, Naraphong W, Thongsuk P, Tantirat P. Comparison of The Effectiveness of Remdesivir Versus Favipiravir on Clinical Improvement And Mortality Among Patients with COVID-19 Pneumonia: A Retrospective Single-Center Study. Journal of Southeast Asian Medical Research. 2023;7:e0151-e0151. doi:10.55374/jseamed.v7.151
  45. Aryati. Aspek Laboratorium COVID-19: pemeriksaan serologi dan PCR. Presented at: Sysmex Webinar Series COVID-19; May 21, 2020.
  46. Syahrini H, Fadjari TH, Dalimoenthe NZ. Neutrophil-Lymphocyte Ratio (NLR) and Lymphocyte-Monocyte Ratio (LMR) as Covid-19 Screening Parameters. IJMLST. 2022;4(1):10-23. doi:10.33086/ijmlst.v4i1.2281
  47. Yang AP, Liu J ping, Tao W qiang, Li H ming. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International Immunopharmacology. 2020;84:106504. doi:10.1016/j.intimp.2020.106504
  48. Rotty LWA, Andrea D, Fujiyanto F, et al. Hubungan Neutrophil Lymphocyte Ratio, Platelet Lymphocyte Ratio, dan Ferritin dengan Pemberian Remdesivir pada Pasien Covid-19 dengan Peningkatan Transaminase. e-CliniC. 2023;11(3):322-329. doi:10.35790/ecl.v11i3.46845
  49. Qadir HK, Jaff HN, Saber HK. Efficacy of Favipiravir in the Treatment of Mild to Moderate COVID-19 Patients in Erbil: A Controlled Clinical Trial. 2022;(1).
  50. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. doi:10.1186/s12967-020-02374-0



DOI: https://doi.org/10.22146/jmpf.87168

Article Metrics

Abstract views : 332 | views : 143

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats